C
Cingulate Inc. (CING)
6.39
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
6.39
0.00 (0.00%)
Cingulate Inc., biofarmatsevtika kompaniyasi, Amerika Qo'shma Shtatlarida diqqat etishmasligi/giperaktivlik buzilishi (DEHB) va tashvishlarni davolash uchun o'zining dori vositalarini yetkazib berish platformasi texnologiyasidan foydalangan holda farmatsevtika mahsulotlarini ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi CTx-1301 (deksmetilfenidat) bo'lib, u bolalar, o'smirlar va kattalardagi DEHBni davolash uchun 3-bosqichli klinik sinovlarda. Shuningdek, u tashvishlarni davolash uchun formulasi ishlab chiqilayotgan CTx-2103 (buspiron)ni ishlab chiqadi. Bundan tashqari, kompaniya DEHBni davolash uchun CTx-1302 (dekstroamfetamin) uchun klinik rejasini boshlashni rejalashtirmoqda. Cingulate Inc. 2012-yilda tashkil etilgan va uning shtab-kvartirasi Kanzas-Siti, Kanzasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer |
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Director |
| Mr. Downey Bryan Wade | Executive VP & Chief Commercial Officer |
| Mr. Nilay D. Patel J.D. | Executive VP, Chief Legal Officer & Chief Compliance Officer |
| Mr. Thomas Dalton | Vice President of Investor & Public Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | S-3 | forms-3.htm |
| 2026-03-18 | 10-K | form10-k.htm |
| 2026-01-28 | 8-K | form8-k.htm |
| 2026-01-15 | 8-K | form8-k.htm |
| 2026-01-12 | S-3 | forms-3.htm |
| 2026-01-02 | 8-K | form8-k.htm |
| 2025-12-15 | 8-K | form8-k.htm |
| 2025-11-13 | 10-Q | form10-q.htm |
| 2025-11-10 | 8-K | form8-k.htm |
| 2025-10-14 | 8-K | form8-k.htm |